Tianming Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tianming Li has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Dongdong Lu
Shanghai Putuo People's Hospital, School of Life Science and Technology, Tongji University, Shanghai 200092, China
1 shared publication Guanglei Song
Department of Central Laboratory, Center of Naval Spectial Medicine, Naval Medical University, Shanghai 200052, China
1 shared publication- Haiyan Li
Department of Breast Surgery, Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
1 shared publication Huihui Sun
Department of Gastroenterology Tongji Institute of Digestive Disease School of Medicine Tongji Hospital Tongji University Shanghai China
1 shared publication- Jiahui An
Department of Microbiology, Immunology and Inflammation, Center for Inflammation and Lung Research, Temple University Lewis Katz School of Medicine
1 shared publication Jianguang Wang
Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
1 shared publication
Latest Publications
- Open Access
- 11 October 2026
- Published by Wiley in Advanced Science
- p. e77955
Lactylation‐Mediated HER2 Stabilization Promotes Trastuzumab Resistance in Gastric Cancer
Trastuzumab is the standard first‐line targeted therapy for human epidermal growth factor receptor 2 (HER2)‐positive gastric cancer (GC). Unfortunately, its clinical efficacy is often compromised by the development of drug resistance. The Warburg effect, a hallmark of cancer metabolism, leads to substantial lactate accumulation. Nevertheless, the impact of metabolic reprogramming on the response to HER2‐targeted therapy remains poorly understood. Here, we demonstrate that AARS1‐mediated lactylation of HER2 promotes trastuzumab resistance in GC. Mechanistically, lactylation at lysine 1171 (K1171) promotes USP11‐mediated deubiquitination and stabilization of HER2 and also enhances the interaction between HER2 and EGFR. Clinically, elevated HER2 K1171 lactylation levels are associated with poor prognosis in GC patients. Inhibiting HER2 K1171 lactylation with L‐alanine or stiripentol—a lactate dehydrogenase inhibitor (LDHi) clinically approved for epilepsy—significantly sensitizes tumor cells to trastuzumab. Furthermore, a cell‐penetrating peptide designed to specifically block HER2 K1171 lactylation potently enhances antitumor efficacy in vivo. In summary, our findings identify HER2 lactylation as a critical mechanism underlying trastuzumab resistance and highlight lactate metabolism as a promising therapeutic target for HER2‐positive GC.
- 11 October 2026
- Published by Wiley in Advanced Science
- p. e77955
Open AccessLactylation‐Mediated HER2 Stabilization Promotes Trastuzumab Resistance in Gastric Cancer
Trastuzumab is the standard first‐line targeted therapy for human epidermal growth factor receptor 2 (HER2)‐positive gastric cancer (GC). Unfortunately, its clinical efficacy is often compromised by the development of drug resistance. The Warburg effect, a hallmark of cancer metabolism, leads to substantial lactate accumulation. Nevertheless, the impact of metabolic reprogramming on the response to HER2‐targeted therapy remains poorly understood. Here, we demonstrate that AARS1‐mediated lactylation of HER2 promotes trastuzumab resistance in GC. Mechanistically, lactylation at lysine 1171 (K1171) promotes USP11‐mediated deubiquitination and stabilization of HER2 and also enhances the interaction between HER2 and EGFR. Clinically, elevated HER2 K1171 lactylation levels are associated with poor prognosis in GC patients. Inhibiting HER2 K1171 lactylation with L‐alanine or stiripentol—a lactate dehydrogenase inhibitor (LDHi) clinically approved for epilepsy—significantly sensitizes tumor cells to trastuzumab. Furthermore, a cell‐penetrating peptide designed to specifically block HER2 K1171 lactylation potently enhances antitumor efficacy in vivo. In summary, our findings identify HER2 lactylation as a critical mechanism underlying trastuzumab resistance and highlight lactate metabolism as a promising therapeutic target for HER2‐positive GC.
- RetractionOpen Access
- 5 April 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31 (5) , 1496
Retraction Notice to: SET1A Cooperates With CUDR to Promote Liver Cancer Growth and Hepatocyte-like Stem Cell Malignant Transformation Epigenetically
- 5 April 2023
- Published by Elsevier in Molecular Therapy
- Vol. 31 (5) , 1496
RetractionOpen AccessRetraction Notice to: SET1A Cooperates With CUDR to Promote Liver Cancer Growth and Hepatocyte-like Stem Cell Malignant Transformation Epigenetically
- 1 March 2021
- Published by Elsevier in Immunobiology
- Vol. 226 (2) , 152055
The level of thymic stromal lymphopoietin and its gene polymorphism are associated with rheumatoid arthritis
- 1 March 2021
- Published by Elsevier in Immunobiology
- Vol. 226 (2) , 152055
The level of thymic stromal lymphopoietin and its gene polymorphism are associated with rheumatoid arthritis